Semaglutide injection (Wegovy; Novo Nordisk) now has an additional indication for the reduction of major adverse cardiovascular events in adults with established CVD and either overweight or obesity, ...
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC.
Weight reduction at one year linked to medication active agent, dosage, treatment indication, persistence of coverage. HealthDay News — For patients with obesity receiving semaglutide or liraglutide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results